These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36269159)

  • 1. Superficial Femoral Artery Endovascular Therapy: 12-Month Primary Patency Rates of Contemporary Endovascular Devices from 25,051 Patients.
    Marmagkiolis K; Kilic ID; Inanc İH; Iliescu C; Ajmal M; Cilingiroglu M
    J Invasive Cardiol; 2022 Nov; 34(11):E784-E792. PubMed ID: 36269159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty.
    Marmagkiolis K; Hakeem A; Choksi N; Al-Hawwas M; Edupuganti MM; Leesar MA; Cilingiroglu M
    Catheter Cardiovasc Interv; 2014 Oct; 84(4):555-64. PubMed ID: 24740749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
    Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Drug-Coated Balloons vs Bare-Metal Stents in Patients With Femoropopliteal Arterial Disease.
    Shishehbor MH; Scheinert D; Jain A; Brodmann M; Tepe G; Ando K; Krishnan P; Iida O; Laird JR; Schneider PA; Rocha-Singh KJ; Zeller T
    J Am Coll Cardiol; 2023 Jan; 81(3):237-249. PubMed ID: 36332764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of endovascular treatment modalities for de novo femoropopliteal lesions in intermittent claudication: A network meta-analysis of randomized controlled trials.
    Zhou Y; Wang J; He H; Li Q; Li M; Li X; Shu C
    Int J Cardiol; 2021 Nov; 343():122-130. PubMed ID: 34461162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
    Krishnan P; Farhan S; Schneider P; Kamran H; Iida O; Brodmann M; Micari A; Sachar R; Urasawa K; Scheinert D; Ando K; Tarricone A; Doros G; Tepe G; Yokoi H; Laird J; Zeller T
    J Am Coll Cardiol; 2022 Sep; 80(13):1241-1250. PubMed ID: 36137674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Endovascular Treatment Modalities for De Novo Femoropopliteal Lesions: A Network Meta-analysis of Randomized Controlled Trials.
    Zhou Y; Zhang Z; Lin S; Xiao J; Ai W; Wang J; Li Y; Li Q
    J Endovasc Ther; 2020 Feb; 27(1):42-59. PubMed ID: 31948375
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass: A paradigm shift in surgical open bypass for chronic limb-threatening ischemia.
    Kobayashi T; Hamamoto M; Okazaki T; Hasegawa M; Fujiwara T; Takahashi S
    Vascular; 2021 Dec; 29(6):905-912. PubMed ID: 33349196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adjunctive drug-coated balloon therapy in endovascular treatment of common femoral artery disease.
    Imran HM; Hyder ON; Soukas PA
    Cardiovasc Revasc Med; 2019 Mar; 20(3):210-214. PubMed ID: 29970328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
    Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directional atherectomy and drug-coated balloon angioplasty vs. bare nitinol stent angioplasty for femoropopliteal artery lesions.
    Wei L; Guo J; Guo L; Qi L; Cui S; Tong Z; Hou P; Gu Y
    Vasa; 2022 Sep; 51(5):275-281. PubMed ID: 35801303
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
    Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
    J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midterm Patency After Femoropopliteal Interventions: A Comparison of Standard and Interwoven Nitinol Stents and Drug-Coated Balloons in a Single-Center, Propensity Score-Matched Analysis.
    Steiner S; Schmidt A; Bausback Y; Piorkowski M; Werner M; Yahiaoui-Doktor M; Banning-Eichenseer U; Scheinert D
    J Endovasc Ther; 2016 Apr; 23(2):347-55. PubMed ID: 26848131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical coherence tomography: guided therapy of in-stent restenosis for peripheral arterial disease.
    Lichtenberg MK; Carr JG; Golzar JA
    J Cardiovasc Surg (Torino); 2017 Aug; 58(4):518-527. PubMed ID: 28382804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
    Liistro F; Grotti S; Porto I; Angioli P; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1295-302. PubMed ID: 24239203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of different endovascular treatments for in-stent restenosis of the femoropopliteal artery: A network meta-analysis.
    He Z; Wang H; Lin F; Ding W; Chen K; Zhang Z
    Vasc Med; 2022 Jun; 27(3):239-250. PubMed ID: 35164613
    [No Abstract]   [Full Text] [Related]  

  • 18. Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries.
    Mohapatra A; Saadeddin Z; Bertges DJ; Madigan MC; Al-Khoury GE; Makaroun MS; Eslami MH
    J Vasc Surg; 2020 Feb; 71(2):560-566. PubMed ID: 31405761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Device Selection in Femoral-Popliteal Arterial Interventions.
    Kim SM; Kim LK; Feldman DN
    Interv Cardiol Clin; 2020 Apr; 9(2):197-206. PubMed ID: 32147120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.